Evidence map›Paper›PMID 38599586›Full record

ArticleAdvanced healthcare materials2025

Immunomodulation Using BMP-7 and IL-10 to Enhance the Mineralization Capacity of Bone Progenitor Cells in a Fracture Hematoma-Like Environment.

Matthias Guido Wiesli, Matthias Werner Huber, Bernhard Weisse, Robert Zboray, Stefanie Kiderlen, Arlyng González-Vázquez, Katharina Maniura-Weber, Markus Rottmar, William Arthur Lackington

Open access · hybridAbstract read
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Matthias Guido WiesliLaboratory for Biointerfaces, Empa - Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, 9014, Switzerland.ORCID 0000-0002-7422-5777
Matthias Werner HuberLaboratory for Biointerfaces, Empa - Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, 9014, Switzerland.
Bernhard WeisseLaboratory for Mechanical Systems Engineering, Empa, Dübendorf, 8600, Switzerland.ORCID 0000-0002-5267-5777
Robert ZborayCenter of X-ray Analytics, Empa, Dübendorf, 8600, Switzerland.ORCID 0000-0003-0811-7396
Stefanie KiderlenProspective Instruments, Dornbirn, 6850, Austria.ORCID 0000-0002-6347-5607
Arlyng González-VázquezTissue Engineering Research Group, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin 2, Ireland.ORCID 0000-0003-0648-5590
Katharina Maniura-WeberLaboratory for Biointerfaces, Empa - Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, 9014, Switzerland.ORCID 0000-0001-7895-3563
Markus RottmarLaboratory for Biointerfaces, Empa - Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, 9014, Switzerland.ORCID 0000-0001-7636-428X
William Arthur LackingtonLaboratory for Biointerfaces, Empa - Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, 9014, Switzerland.
Swiss Federal Laboratories for Materials Science and Technology · CHRoyal College of Surgeons in Ireland · IEVorarlberg University of Applied Sciences · AT

Funding

Empa - Swiss Federal Laboratories for Materials Science and TechnologyON/ORS Kick-Starter Grant #21-351
6 · The paper itself

Abstract

Following biomaterial implantation, a failure to resolve inflammation during the formation of a fracture hematoma can significantly limit the biomaterial's ability to facilitate bone regeneration. This study aims to combine the immunomodulatory and osteogenic effects of BMP-7 and IL-10 with the regenerative capacity of collagen-hydroxyapatite (CHA) scaffolds to enhance in vitro mineralization in a hematoma-like environment. Incubation of CHA scaffolds with human whole blood leads to rapid adsorption of fibrinogen, significant stiffening of the scaffold, and the formation of a hematoma-like environment characterized by a limited capacity to support the infiltration of human bone progenitor cells, a significant upregulation of inflammatory cytokines and acute phase proteins, and significantly reduced osteoconductivity. CHA scaffolds functionalized with BMP-7 and IL-10 significantly downregulate the production of key inflammatory cytokines, including IL-6, IL-8, and leptin, creating a more permissive environment for mineralization, ultimately enhancing the biomaterial's osteoconductivity. In conclusion, targeting the onset of inflammation in the early phase of bone healing using BMP-7 and IL-10 functionalized CHA scaffolds is a promising approach to effectively downregulate inflammatory processes, while fostering a more permissive environment for bone regeneration.

Indexed as

Bone Morphogenetic Protein 7Calcification, PhysiologicFractures, BoneHematomaImmunomodulationInterleukin-10Stem CellsBone RegenerationCollagenDurapatiteHumansOsteogenesisTissue ScaffoldsBMP7 protein, humanBone Morphogenetic Protein 7CollagenDurapatiteIL10 protein, humanInterleukin-10BMP‐7fracture hematomaIL‐10immunomodulationmineralization

Identifiers

PMID38599586
PMCPMC11834375
OpenAlexW4394695403

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.